ArticleAnnals of neurosciences2025
Comparative Analysis of CGRP, VIP and PACAP-38 Levels in Migraine with and Without Aura: A Case-control Study.
Article in Annals of neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Peptidomics profiling identifies endogenous peptides associated with meningeal afferent activation in a chronic migraine mouse model.The journal of headache and pain · 2026Article
- Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond.The journal of headache and pain · 2026Review
- Sex hormone profiles in men with migraine: a cross-sectional, matched cohort study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Migraine pathophysiology involves the release of vasoactive neuropeptides following trigeminovascular system activation. While calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) have been individually studied in migraine, their combined role in differentiating migraine subtypes remains unclear. Purpose: The aim of this study was to evaluate serum levels of CGRP, VIP and PACAP-38 in patients with migraine with aura (MA) and without aura (MO) compared to healthy controls (HC), and assess their potential as diagnostic biomarkers. Methods: This case-control study included 296 participants (266 females, 30 males) divided into three groups: MA ( Results: All three neuropeptides were significantly elevated in migraine patients compared to controls ( Conclusion: The significant elevation of all three neuropeptides, particularly in MA patients, suggests their potential utility as biomarkers for migraine diagnosis and subtype differentiation. These findings support the neurogenic inflammation hypothesis in migraine pathophysiology and may have implications for targeted therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.